ERBB2 and breast cancer: The results revealed that molecular staging was an independent factor (p = 0.012) affecting breast cancer prognosis (p = 0.005) and that patients in the HER2-positive group had a higher risk of recurrent metastasis than those in the triple-positive group (HR = 2.199; 95% CI, 1.296-8.266) (Table 8).